Adverse events associated with RAD treatment
| Adverse event . | WHO grade, n (%) . | N total (%) . | |||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | ||
| Hematotoxicity | |||||
| Anemia | 16 (24) | 31 (47) | 6 (9) | 5 (7.5) | 59 (89) |
| Leukopenia | 11 (17) | 25 (38) | 19 (29) | 5 (7.5) | 60 (91) |
| Neutropenia | 3 (4.5) | 11 (17) | 16 (24) | 16 (24) | 46 (70) |
| Thrombocytopenia | 12 (18) | 10 (15) | 15 (23) | 10 (15) | 47 (71) |
| Nonhematologic toxicity | |||||
| Nausea | 8 | 4 | 0 (0) | 0 (0) | 12 (18) |
| Vomiting | 3 (4.5) | 2 (3) | 0 (0) | 0 (0) | 5 (7.5) |
| Diarrhea | 7 (11) | 4 (6) | 0 (0) | 0 (0) | 11 (17) |
| Infection | 23 (35) | 8 (12) | 6 (9) | 1 (1.5) | 38 (58) |
| Fever | 7 (11) | 2 (3) | 0 (0) | 0 (0) | 9 (14) |
| Fatigue | 26 (39) | 9 (14) | 0 (0) | 0 (0) | 35 (53) |
| Neurotoxicity | 24 (36) | 2 (3) | 0 (0) | 0 (0) | 26 (39) |
| Pain | 15 (23) | 4 (6) | 1 (1.5) | 0 (0) | 20 (30.5) |
| Cardiac events | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Thromboembolism | n.a. | 2 (3) | 1 (1.5) | 0 | 3 (4.5) |
| AEs leading to discontinuation | 0 (0) | (0) | 3 (4.5) | 0 (0) | 3 (4.5) |
| Adverse event . | WHO grade, n (%) . | N total (%) . | |||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | ||
| Hematotoxicity | |||||
| Anemia | 16 (24) | 31 (47) | 6 (9) | 5 (7.5) | 59 (89) |
| Leukopenia | 11 (17) | 25 (38) | 19 (29) | 5 (7.5) | 60 (91) |
| Neutropenia | 3 (4.5) | 11 (17) | 16 (24) | 16 (24) | 46 (70) |
| Thrombocytopenia | 12 (18) | 10 (15) | 15 (23) | 10 (15) | 47 (71) |
| Nonhematologic toxicity | |||||
| Nausea | 8 | 4 | 0 (0) | 0 (0) | 12 (18) |
| Vomiting | 3 (4.5) | 2 (3) | 0 (0) | 0 (0) | 5 (7.5) |
| Diarrhea | 7 (11) | 4 (6) | 0 (0) | 0 (0) | 11 (17) |
| Infection | 23 (35) | 8 (12) | 6 (9) | 1 (1.5) | 38 (58) |
| Fever | 7 (11) | 2 (3) | 0 (0) | 0 (0) | 9 (14) |
| Fatigue | 26 (39) | 9 (14) | 0 (0) | 0 (0) | 35 (53) |
| Neurotoxicity | 24 (36) | 2 (3) | 0 (0) | 0 (0) | 26 (39) |
| Pain | 15 (23) | 4 (6) | 1 (1.5) | 0 (0) | 20 (30.5) |
| Cardiac events | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Thromboembolism | n.a. | 2 (3) | 1 (1.5) | 0 | 3 (4.5) |
| AEs leading to discontinuation | 0 (0) | (0) | 3 (4.5) | 0 (0) | 3 (4.5) |
n.a. indicates not applicable according to Common Terminology Criteria for Adverse Events v3.0.